Followers | 832 |
Posts | 119978 |
Boards Moderated | 17 |
Alias Born | 09/05/2002 |
Monday, December 23, 2019 3:23:55 PM
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine
Ubrelvy may do well in the crowded CGRP arena because it’s oral.
AGN has a second oral CGRP candidate, Atogepant, in development for migraine prevention.
AGN acquired both drugs from MRK in 2015 for what now appears to be a very reasonable price (#msg-115206907).
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM